Cormorant Asset Management

Funding rounds backed by Cormorant Asset Management.

Export CSV
Funding disclosed in full
$633M
Median round
$119M
Rounds in calculation
4
4 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
Epicrispr Biotechnologies

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries CBiotechUnited States
9 participantsabrdnAngelini VenturesCormorant Asset ManagementDuquesne Family OfficeFidelity Management & Research CompanyJanus Henderson InvestorsOctagon CapitalReadout CapitalSanofi Ventures
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries BBiotechUnited States
10 participantsCormorant Asset ManagementFrazier Life SciencesHBM Healthcare InvestmentsKCap Biotechnology FundNovo HoldingsPivotal bioVenture PartnersSoleus CapitalSR OneTrails Edge Capital PartnersWellington Management
Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries CBiotechUnited States
8 participantsBeOne MedicinesCormorant Asset ManagementDeep Track CapitalNovo HoldingsOrbiMedOsage University Partners (OUP)RA Capital ManagementThird Rock Ventures
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries FBiotechUnited States
23 participantsAlderline GroupARCH Venture PartnersCatalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners